Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor Raltegravir

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Ammar, Farah F ^a,b   Abdel Azeim, Safwat ^a   Zargarian, Loussinée ^a   Hobaika, Zeina ^b   Maroun, Richard G ^b   Fermandjian, Serge ^a  

^a Ecole Normale Superieure de Cachan   (France)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

RALTEGRAVIR; VIRUS DNA; 2 PYRROLIDONE DERIVATIVE; INTEGRASE; INTEGRASE INHIBITOR;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISSOCIATION CONSTANT; DNA INTEGRATION; DNA STRAND; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENTHALPY; IC 50; LONG TERMINAL REPEAT; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MODEL; MUTATIONAL ANALYSIS; PROTEIN DNA INTERACTION; SPECTROSCOPY; STRUCTURE ANALYSIS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMISTRY; ENZYMOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DNA, VIRAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; PYRROLIDINONES;

EID: 84863623171     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040223     Document Type: Article

References (73)

1. Goff SP, (1992) Genetics of Retroviral Integration. Annual Review of Genetics 26: 527-544.
2. Katz RA, Skalka AM, (1994) The retroviral enzymes. Annu Rev Biochem 63: 133-173 10.1146/annurev.bi.63.070194.001025 [doi].
3. Pommier Y, Johnson AA, Marchand C, (2005) Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 4: 236-248 nrd1660 [pii];10.1038/nrd1660 [doi].
4. Li X, Krishnan L, Cherepanov P, Engelman A, (2011) Structural biology of retroviral DNA integration. Virology 411: 194-205 S0042-6822(10)00752-X [pii];10.1016/j.virol.2010.12.008 [doi].
5. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, et al. (2002) Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A 99: 6661-6666 10.1073/pnas.092056199 [doi];092056199 [pii].
6. Marchand C, Maddali K, Metifiot M, Pommier Y, (2009) HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem 9: 1016-1037 Abs-010-9-11 [pii].
7. McColl DJ, Chen X, (2010) Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res 85: 101-118 S0166-3542(09)00533-6 [pii];10.1016/j.antiviral.2009.11.004 [doi].
8. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, et al. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369: 1261-1269 S0140-6736(07)60597-2 [pii];10.1016/S0140-6736(07)60597-2 [doi].
9. Koelsch KK, Cooper DA, (2009) Integrase inhibitors in salvage therapy regimens for HIV-1 infection. Curr Opin HIV AIDS 4: 518-523 10.1097/COH.0b013e328331b526 [doi];01222929-200911000-00011 [pii].
10. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, et al. (2008) Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 47: 9345-9354 10.1021/bi800791q [doi].
11. Metifiot M, Marchand C, Maddali K, Pommier Y, (2010) Resistance to integrase inhibitors. Viruses 2: 1347-1366.
12. Reigadas S, Anies G, Masquelier B, Calmels C, Stuyver LJ, et al. (2010) The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions. PLoS One 5: e10311 10.1371/journal.pone.0010311 [doi].
13. Zargarian L, Benleumi MS, Renisio JG, Merad H, Maroun RG, et al. (2003) Strategy to discriminate between high and low affinity bindings of human immunodeficiency virus, type 1 integrase to viral DNA. J Biol Chem 278: 19966-19973.
14. Hobaika Z, Zargarian L, Maroun RG, Mauffret O, Burke TR, et al. (2010) HIV-1 integrase and virus and cell DNAs: complex formation and perturbation by inhibitors of integration. Neurochem Res 35: 888-893 10.1007/s11064-009-0098-2 [doi].
15. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P, (2010) Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464: 232-236 nature08784 [pii];10.1038/nature08784 [doi].
16. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, et al. (1999) Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci U S A 96: 13040-13043.
17. Krishnan L, Li X, Naraharisetty HL, Hare S, Cherepanov P, et al. (2010) Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A 107: 15910-15915 1002346107 [pii];10.1073/pnas.1002346107 [doi].
18. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, et al. (2010) Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A 107: 20057-20062 1010246107 [pii];10.1073/pnas.1010246107 [doi].
19. Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, et al. (2006) Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 49: 1506-1508 10.1021/jm0600139 [doi].
20. Da Silva D, Van WL, Breilh D, Reigadas S, Anies G, et al. (2010) HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 65: 1262-1269 dkq099 [pii];10.1093/jac/dkq099 [doi].
21. Metifiot M, Johnson B, Smith S, Zhao XZ, Marchand C, et al. (2011) MK-0536 inhibits HIV-1 integrases resistant to raltegravir. Antimicrob Agents Chemother 55: 5127-5133 AAC.05288-11 [pii];10.1128/AAC.05288-11 [doi].
22. Vacca J, Wai J, Fisher T, Embrey M, Hazuda D, et al. (2007) Discovery of MK-2048 - subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitors. Poster discussion: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Abstract no WEPEA088.
23. Johns B, Kawasuiji T, Taishi T, Yoshida H, Garvey E, et al. (2010) The discovery of S/GSK1349572: a once-daily next generation integrase inhibitor with a superior resistance profile. in 17th Conference on Retroviruses and Opportunistic Infections, SanFrancisco, CA.
24. Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, Pommier Y, et al. (2011) Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 80: 565-572 mol.111.073189 [pii];10.1124/mol.111.073189 [doi].
25. Espeseth AS, Felock P, Wolfe A, Witmer M, Grobler J, et al. (2000) HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A 97: 11244-11249 10.1073/pnas.200139397 [doi];200139397 [pii].
26. Fitzkee NC, Masse JE, Shen Y, Davies DR, Bax A, (2010) Solution conformation and dynamics of the HIV-1 integrase core domain. J Biol Chem 285: 18072-18084 M110.113407 [pii];10.1074/jbc.M110.113407 [doi].
27. Monnot M, Mauffret O, Simon V, Lescot E, Psaume B, et al. (1991) DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 266: 1820-1829.
28. Hess B, Kutzner C, Van Der Spoel D, Lindahl E, (2008) GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. J Chem Theory Comput 4: 435-447.
29. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, et al. (2010) Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78: 1950-1958 10.1002/prot.22711 [doi].
30. Srinivasan J, Cheatham TE, Cieplak P, Kollman PA, Case DA, (1998) Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate-DNA Helices. J Am Chem Soc 120: 9401-9409.
31. Massova I, Kollman PA, (1999) Computational Alanine Scanning To Probe Protein-Protein Interactions: A Novel Approach To Evaluate Binding Free Energies. J Am Chem Soc 121: 8133-8143.
32. Hou T, Wang J, Li Y, Wang W, (2011) Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 51: 69-82.
33. Xue W, Liu H, Yao X, (2012) Molecular mechanism of HIV-1 integrase-vDNA interactions and strand transfer inhibitor action: A molecular modeling perspective. J Comput Chem 33: 527-536 10.1002/jcc.22887 [doi].
34. Dicker IB, Samanta HK, Li Z, Hong Y, Tian Y, et al. (2007) Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J Biol Chem 282: 31186-31196 M704935200 [pii];10.1074/jbc.M704935200 [doi].
35. Scottoline BP, Chow S, Ellison V, Brown PO, (1997) Disruption of the terminal base pairs of retroviral DNA during integration. Genes Dev 11: 371-382.
36. Katz RA, Merkel G, Andrake MD, Roder H, Skalka AM, (2011) Retroviral integrases promote fraying of viral DNA ends. J Biol Chem 286: 25710-25718 M111.229179 [pii];10.1074/jbc.M111.229179 [doi].
37. Bujacz G, Jaskolski M, Alexandratos J, Wlodawer A, Merkel G, et al. (1996) The catalytic domain of avian sarcoma virus integrase: conformation of the active-site residues in the presence of divalent cations. Structure 4: 89-96.
38. Liu LF, (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375 10.1146/annurev.bi.58.070189.002031 [doi].
39. Pommier Y, Leo E, Zhang H, Marchand C, (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17: 421-433 S1074-5521(10)00161-4 [pii];10.1016/j.chembiol.2010.04.012 [doi].
40. Bujalowski W, Lohman TM, (1987) A general method of analysis of ligand-macromolecule equilibria using a spectroscopic signal from the ligand to monitor binding. Application to Escherichia coli single-strand binding protein-nucleic acid interactions. Biochemistry 26: 3099-3106.
41. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA, (2004) Development and testing of a general amber force field. J Comput Chem 25: 1157-1174 10.1002/jcc.20035 [doi].
42. Wang J, Wang W, Kollman PA, Case DA, (2006) Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 25: 247-260 S1093-3263(05)00173-7 [pii];10.1016/j.jmgm.2005.12.005 [doi].
43. Roothaan CCJ, (1951) New Developments in Molecular Orbital Theory. Rev Mod Phys 23: 69-89.
44. Rassolov VA, Ratner MA, Pople JA, Redfern PC, Curtiss LA, (2001) 6-31G* Basis Set for Third-Row Atoms. J Comput Chem 22: 976-984.
45. Humphrey W, Dalke A, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38 0263785596000185 [pii].
46. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, (1983) Comparison of Simple Potential Functions for Simulating Liquid Water. J Chem Phys 79: 926-935.
47. Darden T, Darrin Y, Pedersen L, (1993) Particle mesh Ewald: An N. log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089-10092.
48. Hess B, Bekker H, Berendsen HJ, Fraaije JG, (1997) LINCS: A linear constraint solver for molecular simulations. J Comput Chem 18: 1463-1472.
49. Bussi G, Donadio D, Parrinello M, (2007) Canonical sampling through velocity rescaling. J Chem Phys 126: 014101-014107 10.1063/1.2408420 [doi].
50. Parrinello M, Rahman A, (1981) Polymorphic transitions in single crystals: A new molecular dynamics method. J App Phys 52: 7182-7190.
51. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, et al. (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33: 889-897 ar000033j [pii].
52. Hurley LH, (2002) DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2: 188-200 10.1038/nrc749 [doi].
53. Dougherty G, Pigram WJ, (1982) Spectroscopic analysis of drug-nucleic acid interactions. CRC Crit Rev Biochem 12: 103-132.
54. Wilson WD, Tanious FA, Barton HJ, Wydra RL, Jones RL, et al. (1990) The interaction of unfused polyaromatic heterocycles with DNA: intercalation, groove-binding and bleomycin amplification. Anticancer Drug Des 5: 31-42.
55. Hertzberg RP, Caranfa MJ, Hecht SM, (1989) On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 28: 4629-4638.
56. Fasman GD, (1996) Circular dichroism and the conformationnal analysis of biomolecules New York Plenum Press.
57. Berova N, Nakanishi K, Woody RW, (2000) Circular dichroism: principles and applications. Wiley-VCH, New York.
58. Monnot M, Mauffret O, Lescot E, Fermandjian S, (1992) Probing intercalation and conformational effects of the anticancer drug 2-methyl-9-hydroxyellipticinium acetate in DNA fragments with circular dichroism. Eur J Biochem 204: 1035-1039.
59. Heyduk T, Lee JC, (1990) Application of fluorescence energy transfer and polarization to monitor Escherichia coli cAMP receptor protein and lac promoter interaction. Proc Natl Acad Sci U S A 87: 1744-1748.
60. Hill JJ, Royer CA, (1997) Fluorescence approaches to study of protein-nucleic acid complexation. Methods Enzymol 278: 390-416.
61. Langley DR, Samanta HK, Lin Z, Walker MA, Krystal MR, et al. (2008) The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors. Biochemistry 47: 13481-13488 10.1021/bi801372d [doi].
62. Renisio JG, Cosquer S, Cherrak I, El AS, Mauffret O, et al. (2005) Pre-organized structure of viral DNA at the binding-processing site of HIV-1 integrase. Nucleic Acids Res 33: 1970-1981 33/6/1970 [pii];10.1093/nar/gki346 [doi].
63. Calladine CR, Drew HR, (1992) Understanding DNA: The Molecule and How It Works. Academic Press, London.
64. Ellison V, Brown PO, (1994) A stable complex between integrase and viral DNA ends mediates human immunodeficiency virus integration in vitro. Proc Natl Acad Sci U S A 91: 7316-7320.
65. Harris SA, Gavathiotis E, Searle MS, Orozco M, Laughton CA, (2001) Cooperativity in drug-DNA recognition: a molecular dynamics study. J Am Chem Soc 123: 12658-12663 ja016233n [pii].
66. Treesuwan W, Wittayanarakul K, Anthony NG, Huchet G, Alniss H, et al. (2009) A detailed binding free energy study of 2:1 ligand-DNA complex formation by experiment and simulation. Phys Chem Chem Phys 11: 10682-10693 10.1039/b910574c [doi].
67. Smith GF, (2009) Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design. Prog Med Chem 48: 1-29.
68. Chaires JB, (2006) A thermodynamic signature for drug-DNA binding mode. Arch Biochem Biophys 453: 26-31 S0003-9861(06)00132-9 [pii];10.1016/j.abb.2006.03.027 [doi].
69. Johnson BC, Metifiot M, Pommier Y, Hughes SH, (2012) Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity. Antimicrob Agents Chemother 56: 411-419 AAC.05292-11 [pii];10.1128/AAC.05292-11 [doi].
70. Vink C, van Gent DC, Elgersma Y, Plasterk RH, (1991) Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage. J Virol 65: 4636-4644.
71. Engelman A, Mizuuchi K, Craigie R, (1991) HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 67: 1211-1221 0092-8674(91)90297-C [pii].
72. Vink C, Yeheskiely E, van der Marel GA, van Boom JH, Plasterk RH, (1991) Site-specific hydrolysis and alcoholysis of human immunodeficiency virus DNA termini mediated by the viral integrase protein. Nucleic Acids Res 19: 6691-6698.
73. Agapkina J, Smolov M, Zubin E, Mouscadet JF, Gottikh M, (2004) HIV-1 integrase can process a 3′-end crosslinked substrate. Eur J Biochem 271: 205-211.